An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics

Next-generation multi-specific antibody therapeutics (MSATs) are engineered to combine several functional activities into one molecule to provide higher efficacy compared to conventional, mono-specific antibody therapeutics. However, highly engineered MSATs frequently display poor yields and less fa...

Descrición completa

Detalles Bibliográficos

Principais autores:	Norbert Furtmann, Marion Schneider, Nadja Spindler, Bjoern Steinmann, Ziyu Li, Ingo Focken, Joachim Meyer, Dilyana Dimova, Katja Kroll, Wulf Dirk Leuschner, Audrey Debeaumont, Magali Mathieu, Christian Lange, Werner Dittrich, Jochen Kruip, Thorsten Schmidt, Joerg Birkenfeld
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2021-01-01
Series:	mAbs
Assuntos:	Bispecific antibodies protein engineering developability high throughput screening lab automation data analytics
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/19420862.2021.1955433
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!